PGNY Stock Recent News
PGNY LATEST HEADLINES
Progyny's stock is trailing the S&P 500 thus far in 2024 amongst macro concerns such as the Alabama court ruling on frozen embryos. However, Progyny's Q4 2023 revenue grew by 26%, and the company continues to add clients and increase the number of covered lives. With no debt and ample cash, the company authorized a share repurchase program up to $100 million.
Shares of fertility-solutions firm Progyny are in the red on disappointing guidance. The company says the Alabama court ruling on in vitro fertilization won't affect it.
Progyny, Inc. (PGNY) Q4 2023 Earnings Call Transcript
One of the fun things about writing about stocks for a living is the library of content you can draw upon for inspiration. Back in June 2020, we were deep in the pandemic, so I wrote a piece about cash-rich stocks to buy for peace of mind.
Progyny, Inc. demonstrates strong resilience and sustained growth potential in a weak macro backdrop. The company's revenue grew 37% year-over-year, beating estimates, with strong performance in fertility benefit services and pharmacy revenue. The contract with the federal government presents a major growth opportunity and the potential for upselling.
Progyny (PGNY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 16, 2023, at 10:30 A.M. Eastern Time.
MNTX, PGNY, GFF, RKDA and CYCC have been added to the Zacks Rank #1 (Strong Buy) List on October 17, 2023.
There are several clear reasons to consider Progyny stock. The company's worth is overlooked, making it a sneaky value play for investors. Here's how Progyny's unique position in the industry and financial health make it an attractive acquisition target.
Progyny (PGNY) is well positioned to outperform the market, as it exhibits above-average growth in financials.